fda approval status ghk-cu approved Is Approved? Legal & 2026 Compounding Rules FDA restores non-injectable GHK-Cu to FDA committee recommends 6 of

High-Concentration Topical Protocol For patients who prefer a non-injectable approach, pharmaceutical-grade topical GHK-Cu can be incorporated into a medical-grade skincare protocol

Rung JP, Carlsson A, Rydn Markinhuhta K, Carlsson ML

Threonine 188 is critical for interaction with NAD+ in research-subject NAD+-dependent 15-hydroxyprostaglandin dehydrogenase

A Category 1 designation means there is sufficient evidence to support safe compounding not that the compound is FDA-approved as a drug

Based on the present results, BPC-157 might have an anti-inflammatory and wound healing effect and not a centrally mediated analgesic effect